TEAM

Our Culture

Our people are the core of everything we will accomplish. We are united in our mission to improve patient lives by pushing the scientific boundaries of covalent medicines. Our Hyku community is composed of diverse individuals that hold respect, collaboration and innovation central to our efforts.

The Team

Kleem Chaudhary, PhD
President & CEO

Andrea Zuhl, PhD
VP, Chemical Biology & Proteomics

Amy Shih, PhD
VP, Computational Chemistry

Darren Harvey, PhD
VP, Chemistry

Craig Correll, PhD
VP, Biology

Nadim Shohdy, PhD
VP, Corp Development

Uddhav Shigdel, PhD
Director, Biomolecular Sciences

Fang Gao, PhD
Director, Medicinal Chemistry

Pranoti Gangurde
Director, Cancer Biology

Punit Saraon, PhD
Senior Scientist

Michelle Dubuke, PhD
Principal Scientist

Allison Roper
Manager, Admin/Ops

Kathy Dunsmore
Principal Scientist

Michael Stokes, PhD
Principal Scientist

Anastasia Ignashkina
Chemoproteomics Research Associate

Scientific Founder

Ku-Lung (Ken) Hsu, PhD

Endowed Associate Professor of Chemistry

CPRIT Scholar

The University of Texas at Austin

Board of Directors

Laura Brass, PhD

Managing Director
Novartis Venture Fund

Kleem Chaudhary, PhD

President & CEO
Hyku Biosciences

Laura Tadvalkar, PhD

Managing Director
RA Capital Management

Matthias Van Woensel, PhD

Partner
Droia Ventures

Board Observers

Adam Cotton, PhD

Analyst
Novartis Venture Fund

Rindert Missiaen, PhD

Associate
Droia Ventures

Jonathan Pritz, PhD

Analyst
RA Capital Management

Kou Qin, PhD

Managing Director
Eisai Innovation

Min Shin, PharmD

Director
KB Investment

Anna Turetsky, PhD

Principal, Venture Investments
The Mark Foundation for Cancer Research